Old Web
English
Sign In
Acemap
>
authorDetail
>
Oliver Manzke
Oliver Manzke
Incyte
Internal medicine
Lenalidomide
Medicine
Rituximab
Placebo
3
Papers
0
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
IBCL-131: inMIND: A Phase 3 Study of Tafasitamab + Lenalidomide Add-On to Rituximab vs Placebo + Lenalidomide Add-On to Rituximab for Relapsed/Refractory (R/R) Follicular Lymphoma (FL) or Marginal Zone Lymphoma (MZL)
2021
Clinical Lymphoma, Myeloma & Leukemia
Laurie H. Sehn
Christian W. Scholz
Stefano Luminari
Antonio Salar
Björn E. Wahlin
Ajay K. Gopal
Christophe Bonnet
Marek Trneny
Shankara Paneesha
Oliver Manzke
Francis Seguy
Di Li
Kai Hübel
Show All
Source
Cite
Save
Citations (0)
A phase 3 study to evaluate the efficacy and safety of tafasitamab plus lenalidomide and rituximab versus placebo plus lenalidomide and rituximab in patients with relapsed/refractory (R/R) follicular lymphoma (FL) or marginal zone lymphoma (MZL).
2021
Journal of Clinical Oncology
Laurie H. Sehn
Christian W. Scholz
Stefano Luminari
Antonio Salar
Björn E. Wahlin
Ajay K. Gopal
Christophe Bonnet
Shankara Paneesha
Oliver Manzke
Francis Seguy
Di Li
Kai Hübel
Show All
Source
Cite
Save
Citations (0)
INMIND: A PHASE 3 STUDY OF TAFASITAMAB + LENALIDOMIDE AND RITUXIMAB VS PLACEBO + LENALIDOMIDE AND RITUXIMAB FOR RELAPSED/REFRACTORY FOLLICULAR OR MARGINAL ZONE LYMPHOMA
2021
Hematological Oncology
K Hübel
C. W. Scholz
Stefano Luminari
Antonio Salar
Björn E. Wahlin
Ajay K. Gopal
Christophe Bonnet
Marek Trneny
Shankara Paneesha
Oliver Manzke
Francis Seguy
Di Li
Laurie H. Sehn
Show All
Source
Cite
Save
Citations (0)
1